Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study

Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study

Abstract Background Hepatitis C is curable with direct-acting antivirals (DAAs). However, treatment uptake remains low among marginalized populations such as people who inject drugs. We sought to understand challenges to treatment uptake with DAAs among people living with hepatitis C and compare tre...

Full description

Bibliographic Details
Main Authors:	Tony Antoniou, Cheryl Pritlove, Dana Shearer, Mina Tadrous, Hemant Shah, Tara Gomes
Format:	Article
Language:	English
Published:	BMC 2023-06-01
Series:	International Journal for Equity in Health
Subjects:	Direct acting antivirals Hepatitis C People who inject drugs Qualitative research
Online Access:	https://doi.org/10.1186/s12939-023-01924-4

Similar Items

Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting
by: Elena Yela, et al.
Published: (2024-04-01)

Injecting drug use and hepatitis C virus infection independently increase biomarkers of inflammatory disease risk which are incompletely restored by curative direct-acting antiviral therapy
by: Anna C. Hearps, et al.
Published: (2024-02-01)

Correction: Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study
by: Tony Antoniou, et al.
Published: (2023-10-01)

Initiation of oral hepatitis C virus treatment: Which barriers are pertinent for ambulatory individuals with a history of illicit substance use? A qualitative interview study
by: Selina Barbati, et al.
Published: (2024-01-01)

Interventions to Improve Uptake of Direct-Acting Antivirals for Hepatitis C Virus in Priority Populations: A Systematic Review
by: David Ortiz-Paredes, et al.
Published: (2022-06-01)

Rate of hepatitis C reinfection after successful direct-acting antivirals treatment among people who inject drugs in Spain: the LIVERate study
by: Fernando Chacón, et al.
Published: (2024-11-01)

Comparison of the Efficacies of Direct-Acting Antiviral Treatment for HCV Infection in People Who Inject Drugs and Non-Drug Users
by: Jui-Ting Hsu, et al.
Published: (2022-03-01)

Evaluation of a person-centred, nurse-led model of care delivering hepatitis C testing and treatment in priority settings: a mixed-methods evaluation of the Tasmanian Eliminate Hepatitis C Australia Outreach Project, 2020–2022
by: Joshua Dawe, et al.
Published: (2023-11-01)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
by: Asma Ahmed, et al.
Published: (2015-12-01)

Hepatitis C virus micro‐elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide
by: Chi‐Ming Tai, et al.
Published: (2024-02-01)

Achieving Hepatitis C Micro-Elimination in Chinese Injecting Drug Users: A Dynamic Network Modeling Study
by: Ying Chen, et al.
Published: (2024-12-01)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
by: Chung-Feng Huang, et al.
Published: (2020-07-01)

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
by: Paweł Pabjan, et al.
Published: (2022-01-01)

Chronic Hepatitis C Treatment with New Antiviral Agents
by: Özlem KANDEMİR
Published: (2018-12-01)

Hepatitis C virus risk among young people who inject drugs
by: Pedro Mateu-Gelabert, et al.
Published: (2022-07-01)

Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators
by: Janvier Serumondo, et al.
Published: (2020-06-01)

Incidence of depression in patients with hepatitis C treated with direct-acting antivirals
by: Elfi Egmond, et al.

Direct-Acting Antiviral Agents in Prevention of Maternal–Fetal Transmission of Hepatitis C Virus in Pregnancy
by: Christopher Hartley, et al.
Published: (2024-06-01)

Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic
by: Chi-Ming Tai, et al.
Published: (2022-07-01)

Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents
by: Claudia Westermann, et al.
Published: (2021-08-01)

Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver Cirrhosis
by: Nobuyuki Toshikuni
Published: (2017-05-01)

Hepatitis C Virus and Antiviral Drug Resistance
by: Seungtaek Kim, et al.
Published: (2016-11-01)

Effect of direct-acting antivirals on elastographic measures in patients with chronic hepatitis C virus infection
by: Mohamed M Sakr, et al.
Published: (2019-01-01)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
by: Soon Young Ko, et al.
Published: (2018-12-01)

Ongoing Gaps in the Hepatitis C Care Cascade during the Direct-Acting Antiviral Era in a Large Retrospective Cohort in Canada: A Population-Based Study
by: Ana Maria Passos-Castilho, et al.
Published: (2024-03-01)

Antiviral therapy in chronic hepatitis C virus infection
by: Irina Russu
Published: (2019-09-01)

Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil
by: Vinicius Lins Ferreira, et al.

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence
by: Nevine Ibrahim Musa, et al.
Published: (2020-07-01)

Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literature
by: Mohit Bhatia, et al.
Published: (2020-01-01)

Efficacy of Direct Acting Antivirals (DAA) therapy in patients with recurrent hepatitis C after liver and kidney transplantation: a cross-sectional study
by: Mehdi Kashani, et al.
Published: (2024-10-01)

HCV treatment access among Latinxs who inject drugs: qualitative findings from Boston, Massachusetts, 2016
by: Avni Mittal, et al.
Published: (2019-07-01)

Adolescents with chronic hepatitis C might be good candidates for direct‐acting antiviral therapy
by: Ken Sato, et al.
Published: (2022-04-01)

Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
by: Ghaydaa A. Shehata, et al.
Published: (2022-12-01)

The Outcomes of Direct-acting Antiviral Treatment in 177 Patients with Hepatitis C Virus: A Single-center Experience
by: Ayşin KILINÇ TOKER, et al.
Published: (2023-12-01)

The impact of direct-acting antivirals on quality of life in patients with hepatitis C virus infection: a meta-analysis
by: Na He, et al.
Published: (2022-07-01)

Role of different direct-acting antiviral drugs on hepatitis C virus-associated mixed cryoglobulinemia in Egyptian patients
by: Tarek A Elshazly, et al.
Published: (2019-01-01)

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
by: Christopher Dietz, et al.
Published: (2022-06-01)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
by: Cassia Leal, et al.
Published: (2023-01-01)

Detection of drug resistance mutations of hepatitis C virus in patients with failure of the treatment with direct acting antivirals
by: D. E. Valutite, et al.
Published: (2021-03-01)

Direct-acting antivirals: a new strategy in the treatment of hepatitis C virus infection in patients with cirrhosis
by: Mariana Avricenco
Published: (2019-12-01)